Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 278


LDL cholesterol: controversies and future therapeutic directions.

Ridker PM.

Lancet. 2014 Aug 16;384(9943):607-17. doi: 10.1016/S0140-6736(14)61009-6. Review.


Evaluating cardiovascular event reduction with ezetimibe as an adjunct to simvastatin in 18,144 patients after acute coronary syndromes: final baseline characteristics of the IMPROVE-IT study population.

Blazing MA, Giugliano RP, Cannon CP, Musliner TA, Tershakovec AM, White JA, Reist C, McCagg A, Braunwald E, Califf RM.

Am Heart J. 2014 Aug;168(2):205-12.e1. doi: 10.1016/j.ahj.2014.05.004. Epub 2014 May 15.


Cardiovascular risk in patients achieving low-density lipoprotein cholesterol and particle targets.

Toth PP, Grabner M, Punekar RS, Quimbo RA, Cziraky MJ, Jacobson TA.

Atherosclerosis. 2014 Aug;235(2):585-91. doi: 10.1016/j.atherosclerosis.2014.05.914. Epub 2014 May 22.


Effects of niacin combination therapy with statin or bile acid resin on lipoproteins and cardiovascular disease.

Zambon A, Zhao XQ, Brown BG, Brunzell JD.

Am J Cardiol. 2014 May 1;113(9):1494-8. doi: 10.1016/j.amjcard.2014.01.426. Epub 2014 Feb 11.


A randomized, double-blind, placebo-controlled phase II clinical trial of lovastatin for various endpoints of melanoma pathobiology.

Linden KG, Leachman SA, Zager JS, Jakowatz JG, Viner JL, McLaren CE, Barr RJ, Carpenter PM, Chen WP, Elmets CA, Tangrea JA, Lim SJ, Cochran AJ, Meyskens FL Jr.

Cancer Prev Res (Phila). 2014 May;7(5):496-504. doi: 10.1158/1940-6207.CAPR-13-0189. Epub 2014 Mar 10.


The effect of moderate-dose versus double-dose statins on patients with acute coronary syndrome in China: Results of the CHILLAS trial.

Zhao SP, Yu BL, Peng DQ, Huo Y.

Atherosclerosis. 2014 Apr;233(2):707-12. doi: 10.1016/j.atherosclerosis.2013.12.003. Epub 2014 Jan 8.


Impact of switching treatment from rosuvastatin to atorvastatin on rates of cardiovascular events.

Folse H, Sternhufvud C, Andy Schuetz C, Rengarajan B, Gandhi S.

Clin Ther. 2014 Jan 1;36(1):58-69. doi: 10.1016/j.clinthera.2013.12.003.


Changes in lipoprotein-Associated phospholipase A2 activity predict coronary events and partly account for the treatment effect of pravastatin: results from the Long-Term Intervention with Pravastatin in Ischemic Disease study.

White HD, Simes J, Stewart RA, Blankenberg S, Barnes EH, Marschner IC, Thompson P, West M, Zeller T, Colquhoun DM, Nestel P, Keech AC, Sullivan DR, Hunt D, Tonkin A; LIPID Study Investigators.

J Am Heart Assoc. 2013 Oct 23;2(5):e000360. doi: 10.1161/JAHA.113.000360.


Dyslipidemia, coronary artery calcium, and incident atherosclerotic cardiovascular disease: implications for statin therapy from the multi-ethnic study of atherosclerosis.

Martin SS, Blaha MJ, Blankstein R, Agatston A, Rivera JJ, Virani SS, Ouyang P, Jones SR, Blumenthal RS, Budoff MJ, Nasir K.

Circulation. 2014 Jan 7;129(1):77-86. doi: 10.1161/CIRCULATIONAHA.113.003625. Epub 2013 Oct 20.


Efficacy and safety of morning versus evening dose of controlled-release simvastatin tablets in patients with hyperlipidemia: a randomized, double-blind, multicenter phase III trial.

Kim SH, Kim MK, Seo HS, Hyun MS, Han KR, Cho SW, Kim YK, Hoon Park S.

Clin Ther. 2013 Sep;35(9):1350-60.e1. doi: 10.1016/j.clinthera.2013.06.020. Epub 2013 Aug 30.


Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial.

Bangalore S, Fayyad R, Laskey R, DeMicco D, Deedwania P, Kostis JB, Messerli FH; Treating to New Targets Steering Committee and Investigators.

Eur Heart J. 2014 Jul 14;35(27):1801-8. doi: 10.1093/eurheartj/eht315. Epub 2013 Aug 29.


Levels and changes of HDL cholesterol and apolipoprotein A-I in relation to risk of cardiovascular events among statin-treated patients: a meta-analysis.

Boekholdt SM, Arsenault BJ, Hovingh GK, Mora S, Pedersen TR, Larosa JC, Welch KM, Amarenco P, Demicco DA, Tonkin AM, Sullivan DR, Kirby A, Colhoun HM, Hitman GA, Betteridge DJ, Durrington PN, Clearfield MB, Downs JR, Gotto AM Jr, Ridker PM, Kastelein JJ.

Circulation. 2013 Oct 1;128(14):1504-12. doi: 10.1161/CIRCULATIONAHA.113.002670. Epub 2013 Aug 21.


Evaluation of C-reactive protein before and on-treatment as a predictor of benefit of atorvastatin: a cohort analysis from the Anglo-Scandinavian Cardiac Outcomes Trial lipid-lowering arm.

Sever PS, Poulter NR, Chang CL, Thom SA, Hughes AD, Welsh P, Sattar N; ASCOT Investigators.

J Am Coll Cardiol. 2013 Aug 20;62(8):717-29. doi: 10.1016/j.jacc.2013.02.098.


Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.

Reiner Z.

Nutr Metab Cardiovasc Dis. 2013 Sep;23(9):799-807. doi: 10.1016/j.numecd.2013.05.002. Epub 2013 Aug 9. Review.


A randomized, double-blind study of fenofibric acid plus rosuvastatin compared with rosuvastatin alone in stage 3 chronic kidney disease.

Weinstein DL, Williams LA, Carlson DM, Kelly MT, Burns KM, Setze CM, Lele A, Stolzenbach JC.

Clin Ther. 2013 Aug;35(8):1186-98. doi: 10.1016/j.clinthera.2013.06.013. Epub 2013 Jul 26. Erratum in: Clin Ther. 2013 Nov;35(11):1862.


Pitavastatin in cardiometabolic disease: therapeutic profile.

Masana L.

Cardiovasc Diabetol. 2013;12 Suppl 1:S2. doi: 10.1186/1475-2840-12-S1-S2. Epub 2013 May 30. Review.


Statins in cardiometabolic disease: what makes pitavastatin different?

Ginsberg H.

Cardiovasc Diabetol. 2013;12 Suppl 1:S1. doi: 10.1186/1475-2840-12-S1-S1. Epub 2013 May 30. Review.


Controversies on HDL: should it be a target biomarker in patients with lipid disorders?

Nicholls SJ, Andrews J, Duong M.

Curr Vasc Pharmacol. 2014;12(4):649-52. Review.


Low-density lipoprotein cholesterol: how low can we go?

Sherbet DP, Garg P, Brilakis ES, Banerjee S.

Am J Cardiovasc Drugs. 2013 Aug;13(4):225-32. doi: 10.1007/s40256-013-0013-8. Review.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk